People: Salix Pharmaceuticals Ltd (SLXP.OQ)

SLXP.OQ on NASDAQ Stock Exchange Global Select Market

135.14USD
29 Jan 2015
Change (% chg)

-- (--)
Prev Close
$135.14
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
648,681
52-wk High
$172.97
52-wk Low
$86.00

Search Stocks

D'Alonzo, Thomas 

Brief Biography

Mr. Thomas W. D'Alonzo is Chairman of the Board, Acting Chief Executive Officer of Salix Pharmaceuticals Ltd. He has been appointed as Acting Chief Executive Officer of the Company effective January 30, 2015. From 2005 until 2012, Mr. D’Alonzo served on the board of directors of Amarillo Biosciences, Inc., a public specialty biopharmaceutical company, and Plexigen, Inc., a private diagnostics company. From March 2007 to February 2009, Mr. D’Alonzo served as the Chief Executive Officer and a director of MiMedx Group, Inc., a biomaterial materials company. From May 2006 to April 2007, Mr. D’Alonzo was Chief Executive Officer of DARA BioSciences, Inc., a specialty pharmaceutical company focused on oncology treatment and products, and he served on its board of directors from September 2005 to December 2008. From 2000 to 2007, Mr. D’Alonzo acted as an independent consultant. Prior to that, from 1996 to 1999, Mr. D’Alonzo served as President and Chief Operating Officer of Pharmaceutical Product Development, Inc., or PPD, a global provider of discovery and development services to pharmaceutical and biotechnology companies. Before joining PPD, from 1993 to 1996, he served as President and Chief Executive Officer of GenVec, Inc., a clinical-stage, biopharmaceutical company. From 1983 to 1993, Mr. D’Alonzo held positions of increasing responsibility within Glaxo, Inc., the U.S. division of GSK, a global pharmaceutical and healthcare company, including President. Mr. D’Alonzo received his B.S. in Business Administration from the University of Delaware, and his J.D. from the University of Denver College of Law.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Thomas D'Alonzo

--

Carolyn Logan

6,600,960

Timothy Creech

--

William Forbes

1,968,770

Rick Scruggs

1,802,050

John Chappell

--
As Of 30 Dec 2013
Search Stocks